Genor Biopharma Holdings (FRA:67N0) ROCE %: -7.90% (As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings ROCE %?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 ROCE % is -7.90% as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genor Biopharma Holdings's annualized ROCE % for the quarter that ended in Jun. 2025 was -7.90%.

Genor Biopharma Holdings  (FRA:67N0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genor Biopharma Holdings ROCE % Related Terms

Genor Biopharma Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings ROCE % Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial -163.60 -31.09 -32.63 -42.65 -2.97

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.93 -56.54 -22.10 16.59 -7.90
FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings ROCE % Calculation

Genor Biopharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-4.594/( ( (185.819 - 29.477) + (169.172 - 16.014) )/ 2 )
=-4.594/( (156.342+153.158)/ 2 )
=-4.594/154.75
=-2.97 %

Genor Biopharma Holdings's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-11.368/( ( (169.172 - 16.014) + (159.963 - 25.423) )/ 2 )
=-11.368/( ( 153.158 + 134.54 )/ 2 )
=-11.368/143.849
=-7.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -7.90% mean?
Genor Biopharma Holdings (FRA:67N0) has a ROCE % of -7.90% as of Jun. 2025.
Is Genor Biopharma Holdings' ROCE % too high?
Genor Biopharma Holdings' current ROCE % is -7.90%. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' ROCE % compare to VRTX and REGN?
Genor Biopharma Holdings' ROCE % of -7.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Genor Biopharma Holdings's current ROCE % is -7.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current ROCE % of -7.90%. The current ROCE % is -7.90%. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current ROCE % is -7.90% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price